Vertex Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Vertex's estimated annual revenue is currently $202.6M per year.(i)
  • Vertex's estimated revenue per employee is $145,000

Employee Data

  • Vertex has 1397 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M20N/AN/AN/A
#2
$648.6M377422%$341M$9.5B
#3
$0.9M1043%N/AN/A
#4
$215.9M1489N/AN/AN/A
#5
$4330M16519N/AN/A$45.1B
#6
$2147.5M17242N/AN/AN/A
#7
$70.1M334N/AN/AN/A
#8
$378.3M203535%$691.1M$10B
#9
$16.4M1170%$91.8MN/A
#10
$24.3M121N/AN/AN/A
#11
$406.1M163220%$220M$5.2B
#12
$76.6M431116%$229.9M$1.2B
#13
$79.7M43325%$7.5MN/A
#14
$308.5M118048%$279.7M$18.6B
#15
$6.8M47N/AN/AN/A
#16
$1.3M5N/AN/AN/A
#17
$40.4M201N/AN/AN/A
#18
$14.9M103N/AN/AN/A
#19
$20.8M149-7%$24.9MN/A
#20
$1.6M8N/AN/AN/A

keywords:saas

N/A

Total Funding

1397

Number of Employees

$202.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vertex News

2022-04-19 - The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals

Stocks recently featured in the blog include: Johnson & Johnson JNJ, Eli Lilly LLY, Vertex Pharmaceuticals VRTX and Deciphera...

2022-04-17 - Health Canada approves Vertex's Trikafta for cystic fibrosis in ...

Vertex's Trikafta was found to be well-tolerated in a Phase III trial in CF patients aged six to 11 years. Credit: Vertex Pharmaceuticals...

2022-04-06 - Vertex CEO Kewalramani nabs more than $15M in 2021 pay ...

In her first full year at the top of cystic fibrosis juggernaut Vertex Pharmaceuticals, CEO Reshma Kewalramani has collected a pay package that rivals...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$749.6M19830%N/A
#2
$563.5M2875N/AN/A
#3
$563.5M2875N/AN/A
#4
$418.8M2888N/AN/A
#5
$1521.8M4026N/AN/A